+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Regional Outlook and Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 226 Pages
  • August 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5997328
The Global Tuberculosis Diagnostics Market size is expected to reach $3 billion by 2031, rising at a market growth of 4.7% CAGR during the forecast period.

Despite having a lower TB incidence than other regions, North America’s market is driven by advanced healthcare systems, high levels of awareness, and strong public health initiatives focused on TB elimination. The U.S., in particular, has made significant investments in TB research and development, leading to the availability of cutting-edge diagnostic technologies. Consequently, the North American region would acquire nearly 30% of the total market share by 2031.



Tuberculosis (TB) continues to be a substantial global health issue, with a particularly high incidence rate in developing countries. The impact of TB is not confined to health alone; it also has significant social and economic consequences. Hence, the rising incidence of TB will increase the demand for diagnostics, thereby propelling the expansion of the market.

Additionally, this field has witnessed significant technological advancements in recent years, which have been crucial in enhancing the accuracy, speed, and accessibility of TB detection. The GeneXpert MTB/RIF assay is one of the most prominent examples of molecular diagnostics transforming TB care. Thus, these factors will aid in the growth of the market.

However, Advanced TB diagnostic tools, particularly those based on molecular diagnostics, are often priced beyond the reach of many healthcare systems in low- and middle-income countries (LMICs). The reliance on donor funding also introduces a level of uncertainty and instability in the financing of TB diagnostics. Hence, the high cost of advanced TB diagnostic tools, coupled with limited and unstable funding, presents significant barriers to the widespread adoption of these technologies.

Moreover, in order to meet the urgent needs of the pandemic, resources such as laboratory facilities, personnel, and financial allocations were redirected from tuberculosis (TB) initiatives. This was done because healthcare systems all over the world were unable to cope with the rise of COVID-19 cases. This diversion of resources led to a significant decline in TB testing and diagnosis, as many TB diagnostic facilities were repurposed for COVID-19 testing. Hence, the pandemic had an overall negative impact on the market.

Driving and Restraining Factors

Drivers
  • Increasing incidence of tuberculosis
  • Technological advancements in diagnostics
  • Rising healthcare expenditure globally
Restraints
  • High cost of advanced diagnostic tools
  • Competition from alternative diagnostic methods
Opportunities
  • Global efforts to eliminate TB
  • Push towards Universal Health Coverage (UHC)
Challenges
  • Limited access to healthcare in remote areas
  • Technical and operational challenges

Type Outlook

Based on type, the market is divided into nucleic acid testing, detection of latent infection (skin test & IGRA), detection of drug resistance (DST), phage assay, cytokine detection assay, diagnostic laboratory methods, radiographic method, and others. The phage assay segment procured 18% revenue share in the market in 2023. This method, which utilizes bacteriophages to detect TB bacteria, has gained traction due to its ability to provide quick and reliable results.



End Use Outlook

On the basis of end use, the market is classified into diagnostic laboratories, hospitals & clinics, and others. The hospitals & clinics segment garnered 35% revenue share in the market in 2023. Hospitals and clinics serve as the first point of contact for many TB patients, making them critical for the initial diagnosis and treatment initiation.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment procured a 35% revenue share in the market in 2023. The segment's growth is driven by the high burden of tuberculosis in countries such as India, China, and Indonesia. This necessitates the implementation of ubiquitous and continuous TB diagnostics, as these countries are responsible for a substantial proportion of the global TB case count.

List of Key Companies Profiled

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F.Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation

Market Report Segmentation

By End Use
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others
By Type
  • Detection of Latent Infection (Skin Test & IGRA)
  • Phage Assay
  • Detection of Drug Resistance (DST)
  • Nucleic Acid Testing
  • Radiographic Method
  • Cytokine Detection Assay
  • Diagnostic Laboratory Methods
  • Other Methods
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Tuberculosis Diagnostics Market, by End Use
1.4.2 Global Tuberculosis Diagnostics Market, by Type
1.4.3 Global Tuberculosis Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Global Tuberculosis Diagnostics Market by End Use
4.1 Global Diagnostic Laboratories Market by Region
4.2 Global Hospitals & Clinics Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Tuberculosis Diagnostics Market by Type
5.1 Global Detection of Latent Infection (Skin Test & IGRA) Market by Region
5.2 Global Phage Assay Market by Region
5.3 Global Detection of Drug Resistance (DST) Market by Region
5.4 Global Nucleic Acid Testing Market by Region
5.5 Global Radiographic Method Market by Region
5.6 Global Cytokine Detection Assay Market by Region
5.7 Global Diagnostic Laboratory Methods Market by Region
5.8 Global Other Methods Market by Region
Chapter 6. Global Tuberculosis Diagnostics Market by Region
6.1 North America Tuberculosis Diagnostics Market
6.1.1 North America Tuberculosis Diagnostics Market by End Use
6.1.1.1 North America Diagnostic Laboratories Market by Country
6.1.1.2 North America Hospitals & Clinics Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Tuberculosis Diagnostics Market by Type
6.1.2.1 North America Detection of Latent Infection (Skin Test & IGRA) Market by Country
6.1.2.2 North America Phage Assay Market by Country
6.1.2.3 North America Detection of Drug Resistance (DST) Market by Country
6.1.2.4 North America Nucleic Acid Testing Market by Country
6.1.2.5 North America Radiographic Method Market by Country
6.1.2.6 North America Cytokine Detection Assay Market by Country
6.1.2.7 North America Diagnostic Laboratory Methods Market by Country
6.1.2.8 North America Other Methods Market by Country
6.1.3 North America Tuberculosis Diagnostics Market by Country
6.1.3.1 US Tuberculosis Diagnostics Market
6.1.3.1.1 US Tuberculosis Diagnostics Market by End Use
6.1.3.1.2 US Tuberculosis Diagnostics Market by Type
6.1.3.2 Canada Tuberculosis Diagnostics Market
6.1.3.2.1 Canada Tuberculosis Diagnostics Market by End Use
6.1.3.2.2 Canada Tuberculosis Diagnostics Market by Type
6.1.3.3 Mexico Tuberculosis Diagnostics Market
6.1.3.3.1 Mexico Tuberculosis Diagnostics Market by End Use
6.1.3.3.2 Mexico Tuberculosis Diagnostics Market by Type
6.1.3.4 Rest of North America Tuberculosis Diagnostics Market
6.1.3.4.1 Rest of North America Tuberculosis Diagnostics Market by End Use
6.1.3.4.2 Rest of North America Tuberculosis Diagnostics Market by Type
6.2 Europe Tuberculosis Diagnostics Market
6.2.1 Europe Tuberculosis Diagnostics Market by End Use
6.2.1.1 Europe Diagnostic Laboratories Market by Country
6.2.1.2 Europe Hospitals & Clinics Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Tuberculosis Diagnostics Market by Type
6.2.2.1 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country
6.2.2.2 Europe Phage Assay Market by Country
6.2.2.3 Europe Detection of Drug Resistance (DST) Market by Country
6.2.2.4 Europe Nucleic Acid Testing Market by Country
6.2.2.5 Europe Radiographic Method Market by Country
6.2.2.6 Europe Cytokine Detection Assay Market by Country
6.2.2.7 Europe Diagnostic Laboratory Methods Market by Country
6.2.2.8 Europe Other Methods Market by Country
6.2.3 Europe Tuberculosis Diagnostics Market by Country
6.2.3.1 Germany Tuberculosis Diagnostics Market
6.2.3.1.1 Germany Tuberculosis Diagnostics Market by End Use
6.2.3.1.2 Germany Tuberculosis Diagnostics Market by Type
6.2.3.2 UK Tuberculosis Diagnostics Market
6.2.3.2.1 UK Tuberculosis Diagnostics Market by End Use
6.2.3.2.2 UK Tuberculosis Diagnostics Market by Type
6.2.3.3 France Tuberculosis Diagnostics Market
6.2.3.3.1 France Tuberculosis Diagnostics Market by End Use
6.2.3.3.2 France Tuberculosis Diagnostics Market by Type
6.2.3.4 Russia Tuberculosis Diagnostics Market
6.2.3.4.1 Russia Tuberculosis Diagnostics Market by End Use
6.2.3.4.2 Russia Tuberculosis Diagnostics Market by Type
6.2.3.5 Spain Tuberculosis Diagnostics Market
6.2.3.5.1 Spain Tuberculosis Diagnostics Market by End Use
6.2.3.5.2 Spain Tuberculosis Diagnostics Market by Type
6.2.3.6 Italy Tuberculosis Diagnostics Market
6.2.3.6.1 Italy Tuberculosis Diagnostics Market by End Use
6.2.3.6.2 Italy Tuberculosis Diagnostics Market by Type
6.2.3.7 Rest of Europe Tuberculosis Diagnostics Market
6.2.3.7.1 Rest of Europe Tuberculosis Diagnostics Market by End Use
6.2.3.7.2 Rest of Europe Tuberculosis Diagnostics Market by Type
6.3 Asia Pacific Tuberculosis Diagnostics Market
6.3.1 Asia Pacific Tuberculosis Diagnostics Market by End Use
6.3.1.1 Asia Pacific Diagnostic Laboratories Market by Country
6.3.1.2 Asia Pacific Hospitals & Clinics Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Tuberculosis Diagnostics Market by Type
6.3.2.1 Asia Pacific Detection of Latent Infection (Skin Test & IGRA) Market by Country
6.3.2.2 Asia Pacific Phage Assay Market by Country
6.3.2.3 Asia Pacific Detection of Drug Resistance (DST) Market by Country
6.3.2.4 Asia Pacific Nucleic Acid Testing Market by Country
6.3.2.5 Asia Pacific Radiographic Method Market by Country
6.3.2.6 Asia Pacific Cytokine Detection Assay Market by Country
6.3.2.7 Asia Pacific Diagnostic Laboratory Methods Market by Country
6.3.2.8 Asia Pacific Other Methods Market by Country
6.3.3 Asia Pacific Tuberculosis Diagnostics Market by Country
6.3.3.1 China Tuberculosis Diagnostics Market
6.3.3.1.1 China Tuberculosis Diagnostics Market by End Use
6.3.3.1.2 China Tuberculosis Diagnostics Market by Type
6.3.3.2 Japan Tuberculosis Diagnostics Market
6.3.3.2.1 Japan Tuberculosis Diagnostics Market by End Use
6.3.3.2.2 Japan Tuberculosis Diagnostics Market by Type
6.3.3.3 India Tuberculosis Diagnostics Market
6.3.3.3.1 India Tuberculosis Diagnostics Market by End Use
6.3.3.3.2 India Tuberculosis Diagnostics Market by Type
6.3.3.4 South Korea Tuberculosis Diagnostics Market
6.3.3.4.1 South Korea Tuberculosis Diagnostics Market by End Use
6.3.3.4.2 South Korea Tuberculosis Diagnostics Market by Type
6.3.3.5 Singapore Tuberculosis Diagnostics Market
6.3.3.5.1 Singapore Tuberculosis Diagnostics Market by End Use
6.3.3.5.2 Singapore Tuberculosis Diagnostics Market by Type
6.3.3.6 Malaysia Tuberculosis Diagnostics Market
6.3.3.6.1 Malaysia Tuberculosis Diagnostics Market by End Use
6.3.3.6.2 Malaysia Tuberculosis Diagnostics Market by Type
6.3.3.7 Rest of Asia Pacific Tuberculosis Diagnostics Market
6.3.3.7.1 Rest of Asia Pacific Tuberculosis Diagnostics Market by End Use
6.3.3.7.2 Rest of Asia Pacific Tuberculosis Diagnostics Market by Type
6.4 LAMEA Tuberculosis Diagnostics Market
6.4.1 LAMEA Tuberculosis Diagnostics Market by End Use
6.4.1.1 LAMEA Diagnostic Laboratories Market by Country
6.4.1.2 LAMEA Hospitals & Clinics Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Tuberculosis Diagnostics Market by Type
6.4.2.1 LAMEA Detection of Latent Infection (Skin Test & IGRA) Market by Country
6.4.2.2 LAMEA Phage Assay Market by Country
6.4.2.3 LAMEA Detection of Drug Resistance (DST) Market by Country
6.4.2.4 LAMEA Nucleic Acid Testing Market by Country
6.4.2.5 LAMEA Radiographic Method Market by Country
6.4.2.6 LAMEA Cytokine Detection Assay Market by Country
6.4.2.7 LAMEA Diagnostic Laboratory Methods Market by Country
6.4.2.8 LAMEA Other Methods Market by Country
6.4.3 LAMEA Tuberculosis Diagnostics Market by Country
6.4.3.1 Brazil Tuberculosis Diagnostics Market
6.4.3.1.1 Brazil Tuberculosis Diagnostics Market by End Use
6.4.3.1.2 Brazil Tuberculosis Diagnostics Market by Type
6.4.3.2 Argentina Tuberculosis Diagnostics Market
6.4.3.2.1 Argentina Tuberculosis Diagnostics Market by End Use
6.4.3.2.2 Argentina Tuberculosis Diagnostics Market by Type
6.4.3.3 UAE Tuberculosis Diagnostics Market
6.4.3.3.1 UAE Tuberculosis Diagnostics Market by End Use
6.4.3.3.2 UAE Tuberculosis Diagnostics Market by Type
6.4.3.4 Saudi Arabia Tuberculosis Diagnostics Market
6.4.3.4.1 Saudi Arabia Tuberculosis Diagnostics Market by End Use
6.4.3.4.2 Saudi Arabia Tuberculosis Diagnostics Market by Type
6.4.3.5 South Africa Tuberculosis Diagnostics Market
6.4.3.5.1 South Africa Tuberculosis Diagnostics Market by End Use
6.4.3.5.2 South Africa Tuberculosis Diagnostics Market by Type
6.4.3.6 Nigeria Tuberculosis Diagnostics Market
6.4.3.6.1 Nigeria Tuberculosis Diagnostics Market by End Use
6.4.3.6.2 Nigeria Tuberculosis Diagnostics Market by Type
6.4.3.7 Rest of LAMEA Tuberculosis Diagnostics Market
6.4.3.7.1 Rest of LAMEA Tuberculosis Diagnostics Market by End Use
6.4.3.7.2 Rest of LAMEA Tuberculosis Diagnostics Market by Type
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Qiagen N.V
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Thermo Fisher Scientific, Inc
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.6 SWOT Analysis
7.4 Becton, Dickinson, and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.6 SWOT Analysis
7.5 F. Hoffmann-La Roche Ltd
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and Mergers:
7.5.6 SWOT Analysis
7.6 Hologic, Inc
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 DiaSorin S.p.A
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Bruker Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Revvity, Inc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis
Chapter 8. Winning Imperatives for Tuberculosis Diagnostics Market

Companies Mentioned

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation
  • Revvity, Inc.

Methodology

Loading
LOADING...